Imbalance in the Th17/Treg and Cytokine Environment in Peripheral Blood of Patients with Adenocarcinoma and Squamous Cell Carcinoma

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2013 Jan 22

PMID 23335103

Citations 21

Authors

Lei Zhao

Jin Yang

Hui-Ping Wang

Rong-Yu Liu

Affiliations

Soon will be listed here.

Abstract

It has been reported that the imbalance of T helper IL-17-producing cells (Th17 cells)/regulatory T cells (Tregs) was closely associated with advanced tumor growth and poor prognosis in lung cancer, but little is known about whether this imbalance is existed in the peripheral blood of patients with non-small cell lung cancer (NSCLC). Here, the percentage of Treg and Th17 cells, and the expression of transcription factors RORγt and FoxP3 were studied by flow cytometry, real-time PCR, and Western blotting, respectively. Levels of serum cytokines (IL-6, IL-17, IL-10, and TGF-β1) were analyzed by ELISA. The results showed that there was an increase in the percentage of Tregs, the mRNA and protein expression of FoxP3, the level of Treg-related cytokines in patients with NSCLC while compared to that in healthy patients. Moreover, the percentage of Th17 cells, RORγt mRNA, and protein expression were decreased in peripheral blood of NSCLC patients. In addition, Th17/Treg ratio was decreased in lung cancer patients when compared with healthy patients and Th17/Treg ratio was negatively correlated with the stages. Our results indicate that the Th17/Treg balance is abnormal in peripheral blood, which may be important in the development of NSCLC.

Citing Articles

Paclitaxel combined with Compound K inducing pyroptosis of non-small cell lung cancer cells by regulating Treg/Th17 balance.

Wang H, Huang M, Zhu M, Su C, Zhang Y, Chen H Chin Med. 2024; 19(1):26.

PMID: 38360696 PMC: 10870689. DOI: 10.1186/s13020-024-00904-2.

Increased circulating Th17 cell populations in patients with pancreatic ductal adenocarcinoma.

Khan I, Singh N, Gunjan D, Gopi S, Dash N, Gupta S Immunogenetics. 2023; 75(5):433-443.

PMID: 37540314 DOI: 10.1007/s00251-023-01318-4.

Acupuncture regulates the Th17/Treg balance and improves cognitive deficits in a rat model of vascular dementia.

Qiuping L, Pan P, Zhenzhen L, Zhen Z, Xuezhu Z, Shuting L Heliyon. 2023; 9(2):e13346.

PMID: 36816326 PMC: 9929319. DOI: 10.1016/j.heliyon.2023.e13346.

T lymphocyte cell: A pivotal player in lung cancer.

Wu Y, Yuan M, Wang C, Chen Y, Zhang Y, Zhang J Front Immunol. 2023; 14:1102778.

PMID: 36776832 PMC: 9911803. DOI: 10.3389/fimmu.2023.1102778.

Propofol maintains Th17/Treg cell balance in elderly patients undergoing lung cancer surgery through GABAA receptor.

Cui C, Zhang D, Sun K, Zhu Y, Xu J, Kang Y BMC Immunol. 2022; 23(1):58.

PMID: 36434505 PMC: 9701037. DOI: 10.1186/s12865-022-00490-8.

References

Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T . FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007; 13(3):902-11. DOI: 10.1158/1078-0432.CCR-06-2363. View

Gaur P, Qadir G, Upadhyay S, Singh A, Shukla N, Das S . Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr). 2012; 35(5):335-43. DOI: 10.1007/s13402-012-0093-5. View

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A . Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203(7):1693-700. PMC: 2118333. DOI: 10.1084/jem.20060468. View

Maniati E, Soper R, Hagemann T . Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene. 2010; 29(42):5653-62. PMC: 2962667. DOI: 10.1038/onc.2010.367. View

Jacobs J, Nierkens S, Figdor C, de Vries I, Adema G . Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol. 2012; 13(1):e32-42. DOI: 10.1016/S1470-2045(11)70155-3. View

Zamarron B, Chen W . Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011; 7(5):651-8. PMC: 3107473. DOI: 10.7150/ijbs.7.651. View

Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T . CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005; 14(5):1269-73. View

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S . Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009; 114(6):1141-9. PMC: 2723011. DOI: 10.1182/blood-2009-03-208249. View

10.

Nistala K, Moncrieffe H, Newton K, Varsani H, Hunter P, Wedderburn L . Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008; 58(3):875-87. PMC: 2675006. DOI: 10.1002/art.23291. View

11.

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

12.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

13.

Zou W, Restifo N . T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010; 10(4):248-56. PMC: 3242804. DOI: 10.1038/nri2742. View

14.

Woo E, Yeh H, Chu C, Schlienger K, Carroll R, Riley J . Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002; 168(9):4272-6. DOI: 10.4049/jimmunol.168.9.4272. View

15.

Lee W, Wu T, Chou H, Yu M, Hsu P, Hsu H . The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma. Surgery. 2011; 151(2):213-22. DOI: 10.1016/j.surg.2011.07.029. View

16.

Woo E, Chu C, Goletz T, Schlienger K, Yeh H, Coukos G . Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61(12):4766-72. View

17.

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View

18.

Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K . Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010; 5(5):585-90. DOI: 10.1097/JTO.0b013e3181d60fd7. View

19.

Petersen R, Campa M, Sperlazza J, Conlon D, Joshi M, Harpole Jr D . Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107(12):2866-72. DOI: 10.1002/cncr.22282. View

20.

Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R . Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008; 14(21):6770-9. DOI: 10.1158/1078-0432.CCR-08-1156. View